The absence of serum C3 and C4 complement assays and ANA and dsDNA antibodies, at onset or dynamically, represented a limitation in the systematic evaluation of the patient, not only for early diagnosis but also for assessing the evolutionary phases of SLE: active or latent. This evidence concerns the gene C4A and systemic lupus erythematosus.